# Cannabinoid Therapeutics in HIV: Strong Pain Trials, an Appetite Literature From Another Era, and Interaction Data That Has Not Been Updated

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabis-for-hiv-aids-evidence/
> **Published:** 2026-09-04T22:51:57-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:40:11-04:00
> **Clinical Summary:** Cannabis for HIV: the neuropathic pain trials hold up, the appetite evidence is from the wasting era, and interaction data predate current regimens.

---

CED Clinical Relevance #68Moderate Clinical RelevanceCannabis remains widely used by people living with HIV, and most of the evidence cited for it was generated before modern antiretroviral therapy changed what the illness looks like. Separating the parts that still apply from the parts that describe a different disease era is the whole clinical task here.

Cannabinoids have real randomized trial evidence in HIV, and most of it is about pain rather than the appetite and wasting story the field is known for. The appetite trials were run in the early 1990s in patients who were losing weight because their infection was untreated. Modern antiretroviral therapy changed that population substantially, and the interaction data that reassured clinicians in 2002 were generated with drugs that are no longer first-line.

Clinical Insight | CED Clinic

Two randomized placebo-controlled trials of smoked cannabis in HIV-associated sensory neuropathy produced the clearest results in this literature. In Abrams and colleagues’ trial in *Neurology*, 52 percent of the cannabis group achieved more than 30 percent pain reduction versus 24 percent on placebo. In Ellis and colleagues’ crossover trial in *Neuropsychopharmacology*, the corresponding proportions were 46 percent and 18 percent.

The appetite and weight literature is weaker than its reputation. In the pivotal 1995 dronabinol trial, appetite improved significantly, but weight change did not reach statistical significance, and the trial was conducted in a population defined by untreated infection.

HIV and AIDSNeuropathic PainDronabinolDrug InteractionsEvidence Appraisal
AudiencePatients, caregivers, and cliniciansPrimary TopicClinical evidence for cannabinoids in HIV symptom management and its relevance in the antiretroviral eraSource[Read the full source](https://doi.org/10.1212/01.wnl.0000253187.66183.9c)
Why This Matters

People living with HIV use cannabis at higher rates than the general population, often for pain, nausea, appetite, and sleep. A clinician asked about it deserves to know which of those indications has trial support specific to HIV and which does not.

The interaction question is the one that has quietly aged out of usefulness. The reassurance most often cited comes from pharmacokinetic work with indinavir and nelfinavir, protease inhibitors that have largely been replaced. Whether that reassurance extends to contemporary regimens has not been tested.

The Neuropathic Pain Evidence Is the Strongest Thing Here

Donald Abrams and colleagues at the University of California, San Francisco ran a prospective randomized placebo-controlled trial of smoked cannabis in painful HIV-associated sensory neuropathy, published in *Neurology* in 2007. Fifty patients completed the protocol, smoking either cannabis at 3.56 percent THC or identical cigarettes from which the cannabinoids had been extracted, three times daily for five days in an inpatient research unit. Daily pain fell by a median of 34 percent on cannabis versus 17 percent on placebo. More than 30 percent pain reduction, the conventional threshold for a clinically meaningful response, was reached by 52 percent of the cannabis group and 24 percent of the placebo group. The first cannabis cigarette alone reduced chronic pain by a median of 72 percent versus 15 percent.

Ronald Ellis and colleagues at the University of California, San Diego replicated the finding with a different design: a phase II double-blind placebo-controlled crossover trial in HIV-associated distal sensory polyneuropathy, published in *Neuropsychopharmacology* in 2009. Thirty-four patients enrolled and 28 completed both treatment arms, using cannabis ranging from 1 to 8 percent THC four times daily for five days during each of two treatment weeks separated by a two-week washout. Pain relief was greater with cannabis, with a median difference of 3.3 points on the Descriptor Differential Scale and an effect size of 0.60. The proportion achieving at least 30 percent relief was 0.46 with cannabis and 0.18 with placebo. Two participants experienced treatment-limiting toxicities.

Both trials enrolled patients whose pain had already failed other analgesic classes, and both continued patients on their existing regimens. That makes these add-on trials in refractory neuropathy, which is a demanding place to show an effect and a fair reflection of how the question presents clinically.

The limits are the sample sizes, the five-day exposure windows, and the route. Neither trial tested oral or vaporized preparations, and neither followed patients long enough to say anything about durability.

The Appetite and Wasting Literature Describes a Different Era

Dronabinol carries a US Food and Drug Administration indication for anorexia associated with weight loss in AIDS, and the trial behind it is worth reading carefully rather than citing from memory. Beal and colleagues randomized 139 patients with AIDS-related anorexia and at least 2.3 kilograms of weight loss to dronabinol 2.5 mg twice daily or placebo, publishing in the *Journal of Pain and Symptom Management* in 1995. Efficacy was evaluable in 88 of them.

Appetite improved by 38 percent above baseline on dronabinol versus 8 percent on placebo, a significant difference. Nausea decreased 20 percent versus 7 percent. Weight, however, was stable on dronabinol while placebo recipients lost a mean of 0.4 kilograms, and that difference did not reach statistical significance. The proportion gaining at least 2 kilograms was 22 percent versus 10.5 percent, also not statistically significant.

So the honest description of the pivotal wasting trial is that it demonstrated an appetite and nausea effect and did not demonstrate a weight effect. Pooled analyses have been kinder. The 2015 *JAMA* systematic review by Whiting and colleagues rated the evidence for weight gain in HIV infection as low quality, and the 2026 *JAMA* review reports a moderate pooled effect of cannabinoids on body weight in HIV and AIDS, with a standardized mean difference of 0.57 (95 percent CI 0.22 to 0.92).

The larger issue is who those trials studied. AIDS wasting syndrome was a manifestation of uncontrolled infection. In a person taking effective antiretroviral therapy with a suppressed viral load, involuntary weight loss is uncommon and, when it occurs, warrants a workup for a specific cause rather than an appetite stimulant. Weight gain on modern regimens is more often the clinical problem than weight loss. Citing 1995 wasting data as though it describes today’s patient is the most common error made on this topic.

Safety and Antiretroviral Interactions: Reassuring, and Out of Date

Abrams and colleagues addressed the safety question directly in a randomized placebo-controlled 21-day inpatient trial in *Annals of Internal Medicine* in 2003. Sixty-seven patients with HIV-1 infection received smoked cannabis at 3.95 percent THC, dronabinol 2.5 mg, or placebo three times daily. Neither smoked nor oral cannabinoids adversely affected HIV RNA levels, CD4 counts, or CD8 counts over the treatment period. The adjusted average change in log10 viral load versus placebo was -0.07 for cannabis and -0.04 for dronabinol, both compatible with no effect.

The companion pharmacokinetic analysis by Kosel and colleagues in *AIDS* examined indinavir and nelfinavir levels in the same participants. Nelfinavir exposure over eight hours changed by -10.2 percent, not significant. Indinavir exposure changed by -14.5 percent and maximum concentration by -14.1 percent, the latter reaching significance. The authors concluded the changes were unlikely to have short-term clinical consequence.

That conclusion is probably still right in spirit, and it rests on drugs that contemporary practice has moved past. Indinavir and nelfinavir are not first-line agents. Modern regimens are anchored on integrase strand transfer inhibitors, and comparable controlled pharmacokinetic studies of cannabis or cannabidiol with those agents have not been published. The absence of a demonstrated interaction is not the same as a demonstration of no interaction.

The practical consequence is modest but real: a patient on a contemporary regimen who uses cannabis or high-dose cannabidiol should have their viral load monitored on the normal schedule and should tell their HIV clinician, and a clinician should not present the 2002 data as though it settles the question for drugs that did not exist then.

Immune Effects, Cognition, and the Claims That Do Not Hold Up

The claim that cannabinoids slow HIV disease progression traces to a single line of primate research, and that research did not replicate. Molina and colleagues reported in *AIDS Research and Human Retroviruses* in 2011 that chronic THC administration decreased early mortality in male rhesus macaques infected with simian immunodeficiency virus. The same group published in 2014 that in eight female macaques the protective effect was absent: no change in mortality, viral load, or CD4 to CD8 ratio, and less weight gain than controls.

An eight-animal study that contradicts an earlier eight-animal study in the other sex is not a foundation for a human claim. Anyone stating that cannabinoids slow HIV progression is extrapolating from primate work that its own authors describe as needing explanation.

The immunosuppression concern runs in the opposite direction and is similarly unresolved in humans. Cannabinoid receptors are expressed on immune cells, and the theoretical concern is legitimate, but the 21-day human trial found no adverse effect on CD4 or CD8 counts and no increase in viral load.

Cognition is where a measurable signal exists. A 2025 study in *Neuropsychology* examined 269 community participants stratified by cannabis use and HIV serostatus. Group comparisons of global and domain-specific neurocognitive performance were not significantly different, but participants who were both cannabis-using and HIV-positive were roughly three times more likely to be classified with a memory impairment than controls, and recent use interacted with serostatus on global and motor performance. The authors describe the effect as modest and call for weighing it against the severity of the symptoms being treated. That is the right framing.

Evidence Snapshot: Cannabinoids in HIVAnchor TrialCannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trialDesignRandomized, placebo-controlled inpatient trial; smoked cannabis 3.56% THC three times daily for 5 daysParticipants50 adults with painful HIV-associated sensory neuropathy completed the trialPrimary ResultMedian daily pain reduction 34% with cannabis versus 17% with placebo (p = 0.03)Responder RateMore than 30% pain reduction in 52% versus 24% (p = 0.04)JournalNeurology, 2007;68(7):515-521PMID / DOI17296917 / 10.1212/01.wnl.0000253187.66183.9cReplicationEllis 2009 crossover trial, 28 completers: effect size 0.60; 46% versus 18% achieved at least 30% relief (PMID 18688212)Appetite EvidenceBeal 1995, 139 randomized: appetite +38% versus +8% (p = 0.015); weight difference not significant (PMID 7730690)Pooled Weight EffectStandardized mean difference 0.57 (0.22 to 0.92) for body weight in HIV and AIDS (JAMA 2026;335(4):345-359)Antiretroviral InteractionIndinavir maximum concentration -14.1% (p = 0.039); nelfinavir changes not significant; both agents no longer first-line (PMID 11872997)
How Strong Is This Evidence?

The neuropathic pain evidence is the strongest in this literature and would be considered respectable in any therapeutic area: two independent randomized placebo-controlled trials, different designs, different institutions, concordant responder rates, in patients already refractory to other analgesics. The weaknesses are sample size, five-day exposure, and reliance on a smoked route that most clinicians would not recommend to a patient with any pulmonary vulnerability.

The appetite evidence is weaker and older than its regulatory status suggests, and the disease-modification evidence does not exist in humans at all. The safety data are reassuring for the era in which they were collected and silent about the drugs used today.

Where This Paper Deserves Skepticism

Both neuropathy trials were small and short. Fifty and 28 completers over five-day treatment periods can establish that an analgesic effect exists; they cannot describe what happens over months, whether tolerance develops, or how the benefit compares with gabapentinoids or duloxetine in a head-to-head design.

Blinding is a persistent problem in any trial of an intoxicating substance. Participants receiving active cannabis can often tell, which inflates subjective outcomes such as pain ratings. The Abrams trial used cannabinoid-extracted cigarettes as placebo, which is better than nothing and does not solve the problem.

The appetite literature carries a further issue: the pivotal trial’s weight outcome was not statistically significant, yet the regulatory indication and three decades of secondary citation have treated the wasting story as settled.

What This Paper Does Not Show

No human study shows that cannabinoids slow HIV disease progression, reduce viral load, or improve immune reconstitution. The primate work sometimes cited for this failed to replicate in female animals from the same laboratory.

No published trial establishes that cannabis is safe to combine with the integrase inhibitor regimens that anchor modern first-line therapy, and no trial has tested cannabinoids for weight loss in virologically suppressed patients, who are a different population from the 1995 trial participants.

How This Fits With the Broader Clinical Conversation

HIV occupies an unusual place in cannabis medicine. It is one of the few indications where cannabinoids hold an actual FDA-approved status, and that status rests on trials whose clinical context has been transformed by effective antiretroviral therapy. The result is a literature that is frequently cited with more confidence than it earns.

The neuropathy finding has aged better. HIV-associated distal sensory polyneuropathy remains common in long-term survivors, is frequently refractory to standard agents, and is one of the few conditions where cannabis has been tested directly against placebo in the relevant population rather than extrapolated from general chronic pain trials.

The most useful thing a clinician can do with this evidence is to sort it by indication instead of by disease. For refractory HIV neuropathy there is direct trial support. For appetite in an untreated or poorly controlled patient there is limited support. For anything framed as slowing the illness there is none.

Dr. Caplan’s Take

When a patient with HIV asks me about cannabis, the first thing I want to know is which symptom we are talking about, because the evidence splits sharply. Painful neuropathy in the feet that has not responded to gabapentin is a reasonable place to have this conversation. Weight loss in someone whose viral load is undetectable is a reason to look for a cause, not a reason to reach for an appetite stimulant.

The wasting literature gets quoted to me constantly, and it comes from a time when people were dying of untreated infection. That is not the patient in front of me. Treating a 1995 trial as current guidance for a virologically suppressed person in 2026 is a category error.

The interaction question is the one I am least comfortable waving off. I have seen the 2002 protease inhibitor data cited as general reassurance for regimens that did not exist when it was collected. I tell patients to keep their HIV clinician informed and to keep their monitoring schedule, which is a low-cost way to handle an unstudied question.

Clinical Bottom Line

For refractory HIV-associated neuropathic pain, two randomized placebo-controlled trials support a real analgesic effect, with roughly half of treated patients reaching a clinically meaningful response versus a fifth to a quarter on placebo. For appetite, the evidence is limited and describes a pre-treatment era population. For disease progression, there is no human evidence. For antiretroviral interactions, the available reassurance concerns drugs that are no longer first-line, so disclosure and routine viral load monitoring remain the sensible approach.

What a Careful Reader Should Take Away

Read this literature by indication and by date. The pain trials are directly relevant and still hold. The appetite trials describe a disease course that effective treatment has largely eliminated, and the safety trials describe a pharmacology that has moved on. Nothing here supports a claim that cannabinoids affect the course of HIV infection itself.

Evidence Interpretation Guide

Table of Contents

- [How to read an evidence base built for a different era of the same disease](#How_to_read_an_evidence_base_built_for_a_different_era_of_the_same_disease)
- [Cannabinoids in HIV, Seen From Eight Angles](#Cannabinoids_in_HIV_Seen_From_Eight_Angles)[Which symptom you are treating changes the answer](#Which_symptom_you_are_treating_changes_the_answer)
- [Sort the literature by indication, then by decade](#Sort_the_literature_by_indication_then_by_decade)
- [Blinding and sample size are the soft spots](#Blinding_and_sample_size_are_the_soft_spots)
- [The wasting claim has outrun its data](#The_wasting_claim_has_outrun_its_data)
- [Effective therapy changed the question](#Effective_therapy_changed_the_question)
- [What a cautious approach looks like](#What_a_cautious_approach_looks_like)
- [The two studies that should exist and do not](#The_two_studies_that_should_exist_and_do_not)
- [An approved indication that outlived its context](#An_approved_indication_that_outlived_its_context)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## How to read an evidence base built for a different era of the same disease

The Research QuestionWhich HIV-related symptoms have randomized trial evidence for cannabinoids, and how much of that evidence still describes patients receiving modern antiretroviral therapy?The Patient QuestionI am living with HIV and considering cannabis. What has actually been tested in people like me, and will it interfere with my medication?The Bottom LineNeuropathic pain has two positive randomized trials. Appetite has one significant result and one nonsignificant weight outcome from 1995. Disease progression has nothing in humans, and the interaction data predate current regimens.
CED Perspective Lens

## Cannabinoids in HIV, Seen From Eight Angles

One evidence base, split sharply by indication and by the era in which it was collected.

Lens OverviewTwo randomized trials support cannabis for HIV-associated neuropathic pain, with roughly half of treated patients reaching meaningful relief. The appetite and wasting evidence comes from the early 1990s, and no human study shows an effect on disease progression.

#### Which symptom you are treating changes the answer

If you have burning or numbness in your feet from HIV-associated neuropathy that has not responded to the usual medications, there are two randomized trials showing cannabis helped roughly half the people who tried it, compared with about a fifth on placebo. That is a real result in a hard condition.

If you are asking about appetite or weight, the evidence is thinner and comes from a period before effective treatment. Unintended weight loss in someone on modern therapy should be investigated rather than treated with an appetite stimulant.

Lens takeawayNeuropathic pain has genuine trial support. Appetite, in a treated patient, does not.

#### Sort the literature by indication, then by decade

The two neuropathy trials enrolled patients refractory to prior analgesic classes and continued their existing regimens, which makes them add-on studies in exactly the population where the question arises. Responder rates of 52 percent versus 24 percent and 46 percent versus 18 percent are consistent across two designs.

The dronabinol indication rests on a trial whose weight endpoint was not statistically significant and whose population was defined by untreated infection. Treat it as historical context rather than as current guidance.

Lens takeawayCite the neuropathy trials with confidence and the wasting trials with a date attached.

#### Blinding and sample size are the soft spots

Participants in a trial of smoked cannabis can usually tell which arm they are in, and the primary outcomes are subjective pain ratings. Cannabinoid-extracted placebo cigarettes reduce the problem without eliminating it.

Fifty and 28 completers is not much to carry a therapeutic recommendation, and five days of treatment says nothing about what happens at week twelve.

Lens takeawayPositive, replicated, and small. All three of those words matter.

#### The wasting claim has outrun its data

In the pivotal dronabinol trial, weight was stable on drug and fell 0.4 kg on placebo, and that difference did not reach significance. Neither did the proportion gaining at least two kilograms. The significant outcomes were appetite and nausea.

A regulatory indication for anorexia associated with weight loss therefore sits on an appetite result rather than a weight result, which is a distinction worth preserving when the trial is cited.

Lens takeawayThe approved indication and the demonstrated outcome are not the same thing.

#### Effective therapy changed the question

AIDS wasting syndrome was a consequence of uncontrolled viral replication. With suppressive antiretroviral therapy it has become uncommon, and weight gain is now a more frequent clinical concern than weight loss in many treated populations.

The pain evidence has aged differently. Distal sensory polyneuropathy persists in long-term survivors and remains difficult to treat, so the 2007 and 2009 trials still address a live problem.

Lens takeawayThe appetite literature describes a disease era; the pain literature describes a current one.

#### What a cautious approach looks like

Tell the HIV clinician, keep the standard viral load and CD4 monitoring schedule, and avoid assuming that older protease inhibitor pharmacokinetic data applies to a current integrase inhibitor regimen.

For a patient with any pulmonary vulnerability, the smoked route used in both trials is not the route to copy. Whether vaporized or oral preparations reproduce the analgesic result in this population has not been tested.

Lens takeawayDisclose, monitor on schedule, and do not assume route equivalence with the trials.

#### The two studies that should exist and do not

A controlled pharmacokinetic study of cannabis and cannabidiol with dolutegravir or bictegravir would resolve the interaction question that clinicians currently answer by analogy to drugs from 2002.

A longer neuropathy trial comparing vaporized or oral cannabinoids against an active comparator such as duloxetine would tell clinicians something the existing five-day placebo trials cannot.

Lens takeawayModern interaction data and a longer active-comparator pain trial are the two obvious gaps.

#### An approved indication that outlived its context

Dronabinol’s approval for AIDS-related anorexia is one of the few formal regulatory endorsements of a cannabinoid, and it is routinely cited as evidence that cannabinoids work. The approval reflects trial data from a treatment era that no longer describes most patients.

That does not make the approval wrong. It does mean that citing it as general evidence for cannabis efficacy, which happens often in advocacy and in marketing, misrepresents what was demonstrated and in whom.

Lens takeawayA standing approval is a regulatory fact, not a current efficacy claim for today’s patients.
Related Reading at CED ClinicContinue exploring the evidence[A Paris Laboratory Found That CBD Blocks HIV in Human Tissue](https://cedclinic.com/cbd-and-hiv-transmission-preclinical-evidence/)

The laboratory work on cannabidiol and HIV, and why a tissue-model result is not a prevention strategy.

[Read the preclinical analysis](https://cedclinic.com/cbd-and-hiv-transmission-preclinical-evidence/)[Relief Is Not the Same as Slowing a Disease](https://cedclinic.com/cannabis-and-disease-progression-symptom-relief/)

The distinction that matters most on this page, applied across the conditions where cannabis is studied.

[See the distinction explained](https://cedclinic.com/cannabis-and-disease-progression-symptom-relief/)[CBD or THC: Sorting the Claimed Advantages by What Randomized Trials Have Shown](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/)

Useful background on which cannabinoid has trial support for which symptom, independent of any one diagnosis.

[Compare the trial evidence](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/)

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

## Frequently Asked Questions

Does cannabis help HIV-related nerve pain?

Two randomized placebo-controlled trials support it. In a 2007 Neurology trial of 50 patients, median daily pain fell 34 percent on smoked cannabis versus 17 percent on placebo, and 52 percent versus 24 percent achieved more than 30 percent relief. A 2009 crossover trial found 46 percent versus 18 percent reaching that threshold, with an effect size of 0.60. Both enrolled patients whose pain had failed other analgesics.

Is dronabinol still useful for weight loss in HIV?

Its approval rests on a 1995 trial in which appetite improved significantly but weight change did not reach statistical significance. That trial enrolled patients with untreated infection and AIDS wasting syndrome. With modern antiretroviral therapy, involuntary weight loss is uncommon and warrants investigation for a specific cause. Pooled analyses report a moderate effect on body weight, though the underlying evidence has been rated low quality.

Does cannabis interfere with antiretroviral medication?

The available data are reassuring and dated. A 2002 study found indinavir maximum concentration fell 14.1 percent and nelfinavir exposure changed by a nonsignificant 10.2 percent, and the authors judged these changes clinically unimportant. Both drugs have been superseded. No comparable published study has tested cannabis or cannabidiol with the integrase inhibitors used in current first-line regimens, so disclosure and routine monitoring remain appropriate.

Does cannabis affect viral load or CD4 count?

In a 21-day randomized inpatient trial of 67 patients published in Annals of Internal Medicine, neither smoked cannabis nor oral dronabinol adversely affected HIV RNA levels, CD4 counts, or CD8 counts. The adjusted change in log10 viral load versus placebo was -0.07 for cannabis, compatible with no effect. The trial was short, so it addresses short-term safety rather than long-term immune consequences.

Can cannabinoids slow the progression of HIV?

No human study shows this. The claim traces to primate research in which chronic THC reduced early mortality in male macaques infected with simian immunodeficiency virus. The same laboratory later reported that in eight female macaques the protective effect was absent, with no change in mortality, viral load, or CD4 to CD8 ratio. That contradiction is not a foundation for a human claim.

Does cannabis worsen thinking or memory in people with HIV?

A 2025 study of 269 participants found no significant group differences in global or domain-specific neurocognitive performance. However, participants who were both cannabis-using and HIV-positive were about three times more likely to be classified with a memory impairment than controls, and recent use interacted with serostatus on global and motor scores. The authors describe the effect as modest and recommend weighing it against symptom severity.

Is smoking the right way to take cannabis for HIV neuropathy?

Both positive neuropathy trials used smoked cannabis under inpatient supervision, so that is what the evidence describes. It is not what most clinicians would recommend, particularly for anyone with pulmonary disease, a common concern in long-term survivors. Whether vaporized or oral preparations reproduce the analgesic result in this population has not been tested in a randomized trial.

What should I tell my HIV doctor about cannabis use?

Tell them what you use, how often, by what route, and for which symptom. Cannabinoids share metabolic pathways with many prescription drugs, and the interaction data for current antiretroviral regimens do not exist. Keeping the standard viral load and CD4 monitoring schedule is the low-cost way to manage an unstudied question, and undisclosed use removes that safeguard.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).